FDA clears additional patient enrollment for Xvivo Heart Assist Transport CAP study

Reuters2026/08/03 07:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xvivo Perfusion won FDA clearance to enroll more patients in its US PRESERVE CAP study of 60 heart transplants using Heart Assist Transport.
CMS renewed cost-recovery authorization, supporting continued clinical use while one-year PRESERVE follow-up data are finalized for a PMA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xvivo Perfusion AB published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA clears additional patient enrollment for Xvivo Heart Assist Transport CAP study

You may also like

Crypto prices